Recent updates on central nervous system prophylaxis in patients with high-risk diffuse large B-cell lymphoma

Efforts to identify clinical and biochemical risk factors associated with CNS relapses have been well documented in the literature. Hollender et al. reported their findings in the pre-rituximab era based on a large group of high-grade Non-Hodgkin’s Lymphoma (Table 2). Factors such as number of extranodal sites, age, serum lactate dehydrogenase levels, serum albumin levels and presence of retroperitoneal lymph nodes were incorporated into this risk stratification model where high risk patients had CNS relapse risks of more than 25% [12].

In the rituximab era, Schmitz and colleagues later developed the Central Nervous System – International Prognostic Index (CNS-IPI) score based on the German High-Grade Non-Hodgkin’s Lymphoma Study Group (DSHNHL) studies and validated it in an independent cohort of patients at the British Columbia Cancer Agency (BCCA) [13]. The CNS-IPI score consists of components in the IPI (International Prognostic Index) score (age, serum LDH levels, performance status, stage and extranodal sites) which were associated with worse outcomes in general, as well as kidneys and/or adrenal gland involvement. The validation study demonstrated that CNS-IPI is highly reproducible to estimate the risk of CNS relapse or progression in DLBCL patients treated with chemotherapy regimen comprising of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (RCHOP) chemotherapy. The two-year rates for development of CNS relapses between the DSHNHL cohort compared against the BCCA cohort were 0.6% vs 0.8% for low risk, 3.4% vs 3.9% for intermediate risk and 10.2% vs 12.0% for high risk [13]. However as the high-risk CNS-IPI group only consists of 55% of CNS relapses in the study cohort, other variables will need to be considered to further refine the selection of patients at high risk of CNS relapses. Importantly, high risk anatomical sites such as breast and testis involvement as well as consideration of cell of origin have a significant impact in prognosticating for CNS relapses [14, 15]. These will be discussed in subsequent sections.

Involvement of certain anatomical locations are also be associated with higher risks of CNS relapses for DLBCL patients. However, not all anatomical locations have been deemed equally high risk to warrant CNS prophylaxis. Kidney and adrenal gland involvement are most recognized and they are integrated into the widely utilized CNS-IPI score. Testicular, bone marrow and breast involvement are also given significant consideration for CNS prophylaxis and are included in recommendations by most guidelines as summarized in Tables 1 and 2 [4, 5, 7, 8, 16‐19]. In a retrospective study by Tomita and colleagues, amongst patients with breast involvement, only 29% would have been considered high risk based on standard IPI score. In contrast, 89% of patients with adrenal and/or kidney involvement were at high-intermediate or high risk by standard IPI score [14]. In the most recent 5th edition of the World Health Organization Classification of Lymphoid Neoplasms, a new term of large Large B-cell lymphomas of immune-privileged sites was coined to distinguish primary B-cell lymphomas of the CNS, vitreoretina and testes in immunocompetent patient from other B-cell lymphomas [20]. This is to give recognition to distinct anatomical barriers, such as the blood–brain barrier (BBB) (Fig. 2), that render these sites an immune sanctuary. Primary B-cell lymphomas from these locations have unique immune regulatory systems resulting in differing pathogenesis as well as immunophenotypical and molecular features that may explain their CNS tropism. This will be discussed in a later section.

Anatomical sites such as the head and neck region (paranasal sinuses, hard palate), areas anatomically close to the CNS (epidural, dura, paravertebral, orbit) and others such as uterine and intravascular involvement have also been reported to have higher risk of CNS relapses [21]. However, these are not as consistently reported across studies, in part due to lower incidences, and hence highlights the importance of physician judgement when considering CNS prophylaxis.

Beyond the use of CNS-IPI score to risk stratify patients, other biomarkers have been evaluated to attempt to further improve the selection of patients at high risk of CNS relapse. Cell-of-origin (COO) subtype has a prognostic impact on the outcomes of DLBCL patients, with the activated B-cell (ABC) subtype or non-germinal centre subtype observed to have worse survival as compared to the germinal centre (GCB) subtype [15, 22]. ABC subtype DLBCL has also been characterized by gene alterations in the CDKN2A gene, affecting NF-κB signalling which may contribute towards CNS tropism [23, 24].

Savage and colleagues reported that ABC subtype DLBCL was associated with increased risk of CNS relapses [25]. This observation was later studied using data from the GOYA Phase III study investigating the efficacy of CD20 antibodies, obinutuzumab against rituximab, in DLBCL patients [26]. High CNS-IPI score and ABC or unclassified subtype DLBCL were independently associated with CNS relapsed (hazard ratios of 4.0; p = 0.02 and 5.2; p = 0.0004) respectively [15]. Combining both parameters in a proposed CNS-IPI-C score, high risk (defined by high CNS-IPI score and ABC/unclassified subtype) was associated with a two-year CNS relapse rate of 15.2% as opposed to 0.5% for low risk (defined by low CNS-IPI score and GCB subtype) [15]. However, considerations should be given when interpreting the results as due to the exclusion of the use of cytotoxic chemotherapy other than CHOP, there may be high risk patients who would have received IV HD-MTX as CNS prophylaxis that were not included in this analysis.

Therefore, risk assessment of CNS relapse for DLBCL patients should perhaps utilize the combination of CNS-IPI score and COO. Further validation studies in larger prospective cohorts are required to inform on this.

Double-hit or triple-hit lymphomas, where there are chromosomal translocations involving MYC, BCL2 and/or BCL6 oncogenes, are associated with a higher risk of CNS recurrence [30]. This group of patients represent about five percent of all newly diagnosed aggressive B-cell lymphomas [30]. In a retrospective analysis, cumulative incidence of CNS involvement was as high as 13% at three years [31]. Among those without documented CNS disease at diagnosis, eventual CNS involvement was lower in those receiving prophylactic intrathecal treatment than those without (5% vs 15% at three years, p = 0.017) [31]. Another analysis by Petrich et al. also showed that in patients without CNS involvement at diagnosis, methotrexate-containing CNS prophylaxis (intravenous or intrathecal) was associated with longer median overall survival (OS) than those without CNS prophylaxis (45 vs 14 months) [32]. This demonstrates that double-hit or triple-hit lymphomas are at increased risk of CNS recurrence and may benefit from CNS prophylaxis.

In patients with double expressing lymphomas, where co-expression of MYC with BCL2 on immunohistochemistry are detected without associated translocations identified on in-situ hybridization, CNS recurrence risks can be as high as nine percent as compared to two percent in non-expressors [25]. This group of patients are more common than double-hit or triple-hit lymphomas, occurring in about one-third of DLBCL cases [25]. The increased risk of CNS relapses in double-expressor lymphomas appears limited to the ABC subtype of DLBCL as well as those with intermediate to high CNS-IPI scores [25, 30]. This shows that while double expression on immunohistochemistry can help identify a group of patients at higher risks of CNS relapses, risk stratification should also include other clinical and molecular factors.

The concept of CNS tropism that may be identified via biological markers is an ongoing area of research [33, 34]. CDKN2A and ATM deletions were identified as critical determinants of CNS tropism with in vivo mouse models [24]. NF-κB hyperactivation was also observed to promote CNS tropism [24]. Elevated levels of ITGA10 and PTEN were observed to be associated with CNS relapses, whereas CD44 and cadherin-11 expression appeared to be protective [35].

Gene alterations in BTG2, PIM1, DUSP2, ETV6 and CXCR4 had been identified in more than 20% of patients with primary CNS lymphoma (PCNSL) in a study by Wang and colleagues [36]. When assessed in a group of patients with high-risk DLBCL who later developed secondary CNS recurrences, 70% were identified to have multiple alterations in these five genes [36].

Mutations in MYD88, CD79B and PIM1 showed a predilection for extranodal sites, including the CNS and other anatomical sites where CNS prophylaxis is usually considered for, such as the breast and testes [37, 38]. These mutations are also noted to be almost exclusive to the ABC subtype of DLBCL, which has been considered a risk factor to be considered for CNS prophylaxis [15, 37].

While this will require further investigation and validation in larger cohorts, perhaps a genomic risk assessment with a selected genetic panel can be developed to identify patients who are at high risk of CNS relapses, warranting CNS prophylaxis. Further understanding of CNS tropism may also help with the future development of diagnostic tools and therapeutics to specifically target these pathways.

Existing evaluation techniques for CNS involvement primarily utilizes cerebrospinal fluid (CSF) sampling for both cytology and flow cytometry to detect CNS disease. However, episodic CSF sampling may not provide adequate yield to determine CNS involvement. CSF specimen may be contaminated with blood, impairing sample quality. CSF cytology has been shown to have a false negative rate of 20–60% [39]. Flow cytometry improves sensitivity for the detection of malignant cells in patients with negative cytology [40‐42]. However, improved detection of disease in CSF specimen is still needed.

The use of circulating deoxyribonucleic acid (ctDNA) has gained traction in recent years. There may be value in detecting ctDNA within CSF to identify those that may be at high risk of CNS relapse. Bobillo and colleagues reported that presence of CSF ctDNA had been detected in the absence of radiological and flow cytometric findings of CSF disease prior to CNS relapse [40]. This suggests that ctDNA may facilitate earlier detection of CNS relapse and allow the provision of appropriate treatment in a timely manner.

Cerebrospinal fluid cell-free DNA (CSF cfDNA) was also reported to have a positive correlation with CNS-IPI score, with high concentrations observed in CNS-IPI high risk [4‐6] group as compared to CNS-IPI low risk (0–3) group [36]. This suggests that presence of CSF cfDNA may be an indication of CNS involvement even if there are no clinical, radiological, or cytological evidence of disease.

As a larger proportion of CNS relapses occur mainly in the brain parenchyma in the rituximab era, CSF analysis may have limited utility in the detection of malignant cells as compared to those with either isolated or concurrent leptomeningeal involvement. Clonotypic, tumour-specific DNA rearrangements of the variable, diversity and joining (VDJ) regions of the immunoglobulin gene loci detected from tumour tissue derived genomic DNA can be used as a biomarker to detect CNS involvement in CSF samples via next-generation sequencing (NGS) based assays [43]. Of the patients who had brain parenchymal disease only, clonotypic DNA was identified even when they had negative CSF evaluation by cytology and flow cytometry [43]. Cumulative risk of CNS recurrence at 12 months from diagnosis was 29% in those who were positive as compared to zero percent in those who tested negative (p = 0.045) [43].

Fluorine-18 fluorodeoxyglucose (¹⁸FDG) positron emission tomography/computed tomography (PET-CT) is an important diagnostic tool for DLBCL patients. It demonstrates involved sites of disease and provides information regarding metabolic activity which can guide biopsy planning. It is also important in determining if bone marrow evaluation is required, as bone marrow evaluation is not commonly conducted upon negative PET-CT results. In a Korean study, authors investigated the value of pre-treatment ¹⁸FDG PET-CT in the prediction of CNS relapses after it was suggested that total lesion glycolysis (TLG) had prognostic value in DLBCL [44, 45]. Total lesion glycolysis is calculated by multiplication of mean standard uptake value (meanSUV) and metabolic tumour volume (MTV). Based on multivariate analysis, high TLG with a threshold margin of 50% (TLG50) was statistically significant as a prognostic factor to predict CNS relapses (p = 0.04) [44]. There was a significant difference in CNS progression free survival (PFS) between high and low TLG50 groups (43.9 vs 65.6 months) [44]. This shows that metabolic and volumetric parameters obtained from PET-CT imaging can provide further prognostic information for DLBCL patients and to identify those at high risk of CNS relapses.

A more recent study demonstrated that an artificial intelligence (AI) based model that incorporates clinical variables and imaging metrics from ¹⁸FDG PET-CT had improved prognostic utility as compared to models with clinical variables alone [46]. High-risk patients with this AI model had significantly increased risk of CNS relapse as compared to low-risk patients with hazard ratio of 5.42 [46]. When CNS-IPI score was combined with this AI model, high-risk patients had a two year CNS relapse probability of up to 17% [46]. This further shows the prognostic value of imaging parameters of PET-CT and the incorporation of AI to facilitate its use in clinical practice.

In the pre-rituximab era, most relapses occur in the leptomeninges [12, 47, 48]. However, in the rituximab era, CNS relapses occur more commonly within the brain parenchyma, accounting for about 60% of all relapses as opposed to 15–20% for leptomeningeal relapses [49, 50]. Rituximab, an anti-CD20 monoclonal antibody is a large molecule with a molecular weight of 145 kilodaltons. Despite achieving high systemic dose levels when infused intravenously, its penetration into the CNS is dismal. CSF concentrations of rituximab reach about 0.1% of serum concentration when delivered at the standard dose of 375 mg/m² [51]. This is largely due to the function of the BBB which does not only represent a single barrier between the blood–brain interface but consists of several levels of barriers occurring both in the macroscopic and microscopic levels.

Generally, only molecules of a low molecular weight of 400–600 daltons can cross the BBB at a microscopic level unlike rituximab [52]. Improved cytotoxicity with the addition of rituximab to cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) chemotherapy may exert its effect on the vasculature within the leptomeninges where tumour cells also reside, leading to reduced leptomeningeal relapses. Molecular weight alone is unlikely to be the only factor contributing to passage of drugs across the BBB and many intricate interactions still unknown to us can affect this, such as the presence of efflux pumps [53]. As drug penetration across the BBB into the brain parenchyma reduces exponentially with increasing distance from blood vessels, the leptomeninges is exposed to high levels of systemically administered rituximab as compared to the brain parenchyma [54]. With a reduction in leptomeningeal relapses and the poor parenchymal penetrance of rituximab, the proportion of brain parenchymal relapses has in turn increased. Improved systemic control may accentuate this observed pattern and this also highlights the need for development of CNS penetrating drugs.

In the pre-rituximab era, the use of intrathecal chemotherapy for CNS prophylaxis in DLBCL patients was largely derived from the experience in Burkitt’s lymphoma and ALL which demonstrated mitigation of leptomeningeal CNS relapses. For Burkitt’s lymphoma, CNS prophylaxis with IT MTX containing regimens in the pre-rituximab era reduced rates of CNS relapses by about 6 to 11 percent [55, 56].

However, in the rituximab era, several studies have shown that the use of intrathecal chemotherapy did not result in reduced incidence of CNS relapses for patients with DLBCL [49, 57]. A reduced incidence of leptomeningeal relapses in the rituximab era, as explained above, may have also contributed to the difficulty in detecting a benefit. Methotrexate, one of the few drugs that can be administered intrathecally, has a low molecular weight of about 450 Daltons, allowing it to penetrate the BBB into the brain parenchyma. While intrathecal administration allows for good drug delivery within the CSF compartment, its efficacy remains dependent on CSF circulation for equal distribution within the CNS. For drugs administrated into the spinal subarachnoid space in the lumbar region, drug levels diminishes as it circulates rostrally, further minimizing its effect in the brain parenchyma [58, 59]. Whilst methotrexate is an attractive therapeutic option given its CNS penetrating properties, its efficacy in the treatment of DLBCL may not necessarily be comparable to other drugs such as rituximab [2].

The complex interface between blood, brain and CSF may contain further barriers for parenchymal penetration of drugs administered intrathecally through the CSF, with drug entry limited not just by diffusion but also efflux transporters and carrier-mediated transport systems [60, 61].

In the rituximab era, isolated CNS relapses in DLBCL patients account for about 70–75% of all CNS relapses with the remaining being concurrent CNS and systemic relapse [49, 62, 63]. In one study, there was no significant difference in the incidence of isolated CNS relapses between those who received RCHOP, CHOP or R-CHOEP (rituximab, cyclophosphamide, doxorubicin, vincristine, etoposide and prednisolone) chemotherapy [63]. There is nevertheless a numerically higher percentage of isolated CNS relapses in those who received rituximab-based chemotherapy as compared to CHOP without rituximab (74.1% vs 69.2%) [63]. This is also observed in the RICOVER-60 trial [27]. Collectively, this could indicate improved systemic control, as well as poor penetrance of rituximab into the CNS. This in turn gives further weight to the need to consider CNS prophylaxis with rituximab-based chemotherapy, to mitigate CNS relapses in this group of patients. As for patients with concurrent CNS and systemic relapses, it is likely that these patients constitute a group with poorer disease biology and worse prognosis overall. This group warrants further refinement of current selection criteria for poor risk disease and intensification of systemic therapy in the first line setting.

The use of IT MTX as CNS prophylaxis in patients with DLBCL or aggressive B-cell lymphomas have been largely extrapolated from treatment regimens of Burkitt’s lymphoma and ALL where it is a standard component. However, its utility as CNS prophylaxis, especially in the rituximab era has been questioned.

A systematic review by Eyre et al. has shown that there are no existing published data that suggests a clear benefit of intrathecal chemotherapy alone (where methotrexate is the main component) as CNS prophylaxis in DLBCL patients undergoing anti-CD20 antibody and anthracycline based immunochemotherapy [49]. This is despite adjusting for confounding factors in a general population of DLBCL patients. Authors did qualify that the available evidence to suggest a genuine lack of benefit is also poor and therefore do not rule out its utility entirely [49]. Given the decreased proportion of CNS relapses occurring in the leptomeninges compared to brain parenchyma as described before, it is plausible that IT MTX as CNS prophylaxis has a diminished benefit in the rituximab era.

Should the role of IT MTX be considered as an alternative CNS prophylaxis, especially in patients who are contraindicated for IV HD-MTX? Such patients may include those with inadequate organ function and those experiencing significant myelosuppression. Elderly patients tend to have poorer organ function reserves and the utility of IT MTX in patients aged 70 years and above has also been reviewed separately [57]. In this study, no clear benefit for IT MTX was observed. Instead, an independent increased risk of infection related admission during systemic treatment was observed with the use of intrathecal CNS prophylaxis [57]. Whilst IT MTX remains a recommendation in some guidelines in those who cannot receive or tolerate IV HD-MTX, caution regarding its risks is to be exercised [7].

In the rituximab era, where there is a higher proportion of brain parenchymal CNS relapses compared to leptomeningeal, IT MTX is unlikely to provide significant intraparenchymal concentrations to achieve adequate CNS prophylaxis. IV HD-MTX therefore aims to provide better concentrations within the brain parenchyma. This has therefore been the preferred route of CNS prophylaxis across major guidelines, as shown earlier. However, is IV HD-MTX effective against CNS relapses? We examine the literature as follows.

In an Italian centre, CNS relapse rates were reported to be 12% in patients without IV HD-MTX as compared to 2.5% for patients who received prophylaxis (p = 0.03) [66]. However, this study has been critiqued for imbalances in the study population characteristics of advanced stage, raised LDH levels and high-risk anatomical locations. In another multicentre study by Ong et al., three-year cumulative incidence of isolated CNS relapse was 14.6% in those who did not receive IV HD-MTX compared to 3.1% in those who did and this was statistically significant (p = 0.032) [67]. A further analysis in propensity score-matched patients also yielded similar results [67]. However, the relatively shorter follow-up time of 20 months for the cohort could potentially underestimate the number of late relapses.

On the other hand, Puckrin et al. demonstrated that there was no significant benefit of IV HD-MTX as CNS prophylaxis in a group of patients at high risk for CNS relapse treated in Alberta, Canada [68]. CNS relapse risk was 11.2% in those with IV HD-MTX as compared to 12.2% in those without. Even after accounting for confounding factors with multivariate analysis and propensity score analyses, there remained no association between IV HD-MTX and CNS relapse [68]. Another Korean study also demonstrated similar findings with the use of IV HD-MTX as CNS prophylaxis (12.4% vs 13.9%) [69]. The conclusions drawn remained the same after propensity score–matched and inverse probability treatment weighting (IPTW) analyses were conducted to overcome potential bias between the treatment groups.

Recently, Lewis et al. presented their findings of a large retrospective study of more than 2400 high-risk aggressive B-Cell lymphoma patients with more than five years of follow-up [70]. They found that for the study population, whilst there was a statistically significant reduction in 5-year risk of CNS progression from 8.5% to 6.9% (HR 0.59 p = 0.014), it was not a clinically meaningful reduction, translating to subjecting 63 patients to CNS prophylaxis in order to prevent one CNS relapse. This statistical significance was also not carried over when analysis was performed in patients that achieved complete response at the end of their frontline treatment, which is a group of patients where the direct effect of CNS prophylaxis with HD-MTX can be examined clearly after attaining good systemic control. A subgroup analysis also demonstrated no reduced risk of CNS progression in patients who received IT MTX, as compared to those who had no CNS prophylaxis (5-year CNS progression risk for IT MTX was 8.0% versus 8.5% in those with no CNS prophylaxis). There was also no difference between risk of CNS progression for patients who received intercalated HD-MTX and those who received it after systemic therapy. The authors accept the challenges in making firm conclusions from a retrospective study, however, recognition is due for their efforts to minimize bias by sound statistical methodology. Whilst this single study does not answer the question definitively, it is increasingly shifting the needle, amidst the body of literature currently available, towards the limited benefit of IV HD-MTX as CNS prophylaxis.

Given the above, the utility of IV HD-MTX in CNS prophylaxis has been cast into doubt. While we cannot exclude the possibility of definite benefit in a group of well selected patients with the highest risks of CNS relapses, it appears that the margin of benefit for most patients receiving IV HD-MTX as CNS prophylaxis is small if any. This may not be sufficient to justify the toxicities and burden imposed on the healthcare system. A randomized controlled trial remains the gold standard to conclusively demonstrate the efficacy of IV HD-MTX but this is inherently challenging to conduct given the low incidence of CNS relapses. Multicentre and multinational retrospective analyses of large populations may be a more realistic and practicable approach to guide treatment practices.

Comparisons between intrathecal and intravenous routes of methotrexate CNS prophylaxis have largely been retrospective. In a single-centre study at the Memorial Sloan Kettering Cancer Centre, DLBCL patients who received RCHOP or RCHOP-like chemotherapy with high risk of CNS relapse determined by CNS-IPI score, high-risk anatomic locations and those with MYC and BCL2 rearrangements were reviewed [62]. Majority of patients (86%) received IT MTX. CNS relapse risk appears to be similar for both routes of administration with five-year CNS relapse risk of 5.6% for IT MTX as compared to 5.2% for IV HD-MTX [62].

Another multicentre study in the US that reviewed 1162 patients across 21 academic centres showed that the majority (77%) of patients received CNS prophylaxis intrathecally [59]. No significant differences in CNS relapses were observed between IT MTX and IV HD-MTX (5.4% vs 6.8% p = 0.40) [59]. Statistical strategies to account for differences between both groups such as propensity score-matching, adjustments for CNS-IPI, number of doses received, and backbone chemo regimen yielded similar findings. As death may represent a competing risk to CNS relapses, authors performed a competing risk analysis and no differences between route of administration was identified as well [64].

Current evidence in the literature suggests that there is no significant differences in CNS relapses between IT MTX and IV HD-MTX. However, this clinical question remains flawed and baseless when neither IT MTX or IV HD-MTX alone have proven significant benefit as CNS prophylaxis. Recommendations of IV HD-MTX in most guidelines are still based on observations of increased parenchymal relapses in the rituximab era as well as the theoretical understanding that IV HD-MTX may offer higher CNS penetration into brain parenchyma. IT MTX is considered only when IV HD-MTX is contraindicated. Even if the benefit of any CNS prophylaxis can be definitively proven, a study of the preferred route of administration would face at least the same, if not more challenges.

IT MTX can provide high CSF drug levels, exerting its effect within the leptomeninges mainly while IV HD-MTX can provide high brain parenchymal penetration. A combined approach has been suggested by Faqah et al. in their single-centre retrospective study in Pakistan [71]. Even though it was not statistically significant, patients who had received both IT MTX and IV HD-MTX appeared to have numerically lowest three-year CNS relapse rates and highest three-year overall survival rates when given with CHOP chemotherapy with or without rituximab [71]. Notably, in this study, rituximab was not mandated in view of drug access issues. Given that rituximab is now the standard of care in the treatment of DLBCL, omission of rituximab will result in suboptimal systemic control and lead to an associated increase in CNS relapses. Therefore, the combined use of both IT MTX and IV HD-MTX may appear more efficacious as it compensates for the poorer overall outcomes in those who did not receive rituximab. This is consistent with the notion that in the pre-rituximab era, combined IT MTX and IV HD-MTX was given as CNS prophylaxis, resulting in reduced CNS recurrences in higher risk patients (by IPI score) [72].

In primary testicular lymphoma, it involves an immunoprivileged site that is not unsimilar to that of the primary CNS lymphoma with many shared clinicopathological and biological features [73]. Hence it is not surprising that PTL have a higher CNS relapse risk of up to 30% [74]. For this group of patients at higher risk of CNS relapse, prophylaxis given with both IT MTX and IV HD-MTX did not offer adequate protection for the majority, suggesting that a combined approach may represent overtreatment without improved protective benefit [73]. However, a recent Phase II study [75] of 54 patients had shown that instead, a combination of intrathecal liposomal cytarabine and IV HD-MTX resulted in a 5-year CNS relapse rate of 0% as compared to 6% in a preceding trial [76] where only IT MTX was utilized.

Overall, risks of a combined approach, both in terms of drug toxicities and the additional procedural risks of a lumbar puncture, may not be justified when the utility of either IT MTX or IV HD-MTX is not clear.

To overcome the challenges with administration of IV HD-MTX, some centres have shared their experiences in modifying how IV HD-MTX is routinely delivered. IV HD-MTX for CNS prophylaxis has been given either in between cycles of RCHOP chemotherapy (intercalated) or at the end of treatment. These practices vary across institutions. However, CNS relapses for DLBCL patients has been observed to occur early and reported to be within six to eight months from diagnosis [15]. Thus, giving CNS prophylaxis as early as possible by intercalating IV HD-MTX with RCHOP chemotherapy cycles has been postulated to provide timely protection against CNS relapses as opposed to end of treatment administration. Intercalating IV HD-MTX may increase toxicities during RCHOP cycles, such as myelosuppression and acute kidney injury (AKI), which will lead to delay in the delivery of systemic chemoimmunotherapy, compromising on treatment intensity which is not ideal. Wilson et al. conducted a retrospective multicentre study to compare these two approaches but no differences in CNS relapse incidence were noted [77]. However, there were increased toxicities and RCHOP delays with the intercalated approach [77].

If intercalation is chosen, it must be noted that patients who received IV HD-MTX more than ten days after RCHOP chemotherapy was associated with higher rates of treatment delays. It has also been shown that IV HD-MTX can be given as early as day 1 of RCHOP without delaying treatment schedules. Lower rates of neutropenic fever and AKI were observed when IV HD-MTX was initiated in Cycle 2 or later.

Administration of IV HD-MTX is often accompanied by the need for a hyperhydration regime with urine alkalinization as well as close monitoring of fluid balances and urine PH. They also require folinic acid rescue and plasma methotrexate clearance monitoring. Whilst patients receiving IV HD-MTX generally requires a hospital admission, there is an increased impetus to transition this to the ambulatory setting which has been described to be safe and feasible with appropriate patient selection.

As discussed earlier, systemic administration of rituximab does not allow for significant CSF concentrations to be achieved due to its large molecular size. Hence, despite the significant improvements in survival outcomes, its role as an active CNS agent when administrated systemically is less impressive.

Comparatively, patients with active leptomeningeal disease may have disruptions in the BBB that may allow for higher CSF concentrations of rituximab when administered systemically, with CSF concentrations reported to increase to 3–4% of serum concentration [51, 85].

There have been case series and reports sharing that administering intrathecal rituximab showed promising efficacy in patients with CNS disease [86‐89]. It has been reported that patients with both leptomeningeal and parenchymal involvement are most likely to progress even with combined intrathecal and intravenous rituximab, whereas those with isolated leptomeningeal disease had high complete remission rates of about 50% with combined intrathecal and intravenous rituximab [90].

We await further investigation regarding the use of intrathecal rituximab as CNS prophylaxis in DLBCL patients [NCT03688451].

In the pre-rituximab era when CHOP chemotherapy was the standard of care, addition of etoposide was an independent prognostic factor for no CNS recurrence [91]. Risk of CNS recurrence was markedly reduced with cyclophosphamide, doxorubicin, vincristine, etoposide and prednisolone (CHOEP) chemotherapy with a relative risk ratio of 0.4 (p = 0.017) [91]. However, it is worth noting that this analysis also included patients with other histological subtypes such as Burkitt’s Lymphoma and other lymphoblastic lymphomas.

Addition of rituximab to CHOP chemotherapy was also shown to reduce the incidence of CNS relapses from 6.9% to 4.1% [92]. In an analysis of patients from the RICOVER-60 trial, risk of CNS relapse was increased without IT MTX if they had not received rituximab [27]. However, if they had received rituximab, risk of CNS relapse was significantly lower with or without IT MTX [27].

Interestingly, intensification of chemotherapy with the addition of both rituximab and etoposide was not observed to have further decrease in CNS relapse rates. A single-centre retrospective study showed CNS relapse rate of 6.2% in rituximab, etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin (R-EPOCH) group and 2.4% in RCHOP group although the difference was not significant (p = 0.301) [93]. The phase III CALGB 50303 trial observed CNS relapse rates of 4.0% in RCHOP group and 3.3% in R-EPOCH group [94]. These observations may indicate that there is a limitation to intensifying systemic treatment with multi-agent chemotherapy alone with regards to CNS control. Combining systemic and intrathecal chemotherapy approaches as well as other methods of achieving better systemic control could be more effective in reducing CNS relapse.

Further intensification of chemotherapy with doxorubicin, cyclophosphamide, vindesine, bleomycin, prednisone (ACVBP) had improved event-free survival (EFS) and OS over standard CHOP chemotherapy in poor-risk aggressive non-Hodgkin’s lymphoma [48]. In this protocol, apart from induction ACVBP, it also includes a sequential consolidation therapy containing CNS active agents such as IV HD-MTX, etoposide, ifosfamide and cytarabine. Patients receiving the ACVBP protocol had lesser CNS progression or relapses compared to those receiving CHOP (RR 2.99; p = 0.002) [48]. In the rituximab era, R-ACVBP also had improved survival over R-CHOP in low-intermediate risk DLBCL [95]. No CNS relapses were noted in the R-ACVBP group as compared to two patients in the R-CHOP group [95]. A joint analysis of data from multi-center clinical trials showed that CNS relapse rates R-ACVBP arm was numerically lower than R-CHOP like regimen arm (1.6% vs 3.9%), although this was not statistically significant (HR2.4; 95% CI: 0.8–7.4; p = 0.118) [96].

In a retrospective study by Puckrin et al., patients who received consolidative autologous transplant or intensive chemoimmunotherapy regimens such as rituximab, cyclophosphamide, doxorubicin, vincristine and high-dose methotrexate (R-CODOX-M), rituximab, ifosfamide, etoposide and cytarabine (R-IVAC) or R-EPOCH demonstrated a trend towards lower risk of CNS relapse [68]. Rates of CNS relapse was 6.0% for both groups of patients compared to 14.6% in those receiving standard RCHOP (p = 0.09) [68]. These patients represent a high-risk group with more than 60% with CNS-IPI of 4–6 and more than 40% with double hit lymphoma [68]. Amongst patients with CNS relapses, 59% had concurrent systemic disease, which may suggests that most CNS relapses occur in the setting of inadequate systemic control [68]. Another retrospective study also observed a trend towards reduced CNS relapse risk with intensive chemoimmunotherapy regimens [97].

While these are promising results, its utility in the front-line setting remains controversial. Not only did upfront consolidation with HDC and autologous HSCT not improve survival as per a meta-analysis, a retrospective Japanese multicentre study also reported similar incidence of CNS relapses [98, 99]. A strong margin of benefit must be demonstrated in a randomized trial to justify the use of HDC and autologous HSCT in reducing CNS recurrence, especially given its toxicities and significant risks of mortality. Even if this is proven as an effective method of reducing CNS recurrence, its use also remains limited to younger and medically fit patients.

CD19-directed chimeric antigen receptor (CAR)-T cell therapy has shown significant progress in recent years in the treatment of DLBCL with phase III studies showing EFS benefit of axicabtagene ciloleucel and lisocabtagene maraleucel in the second line setting over HDC and autologous HSCT [100, 101]. There were significant concerns with the inclusion of DLBCL patients with CNS involvement in view of the known adverse event of immune effector cell-associated neurotoxicity syndrome (ICANS) associated with CAR-T cell therapy. The mechanism of ICANS is postulated to be related to pericytes surrounding endothelial cells along capillary walls that form part of the BBB, which may also express an isoform of CD19 that is targeted by CAR-T cells [102]. However retrospective studies have reported that CAR-T cell therapy in patients with CNS relapses did not have an increase in ICANS and should not be excluded from these studies [103, 104]. It was also described in a patient that interleukin-6 levels had a sevenfold increase in the CSF as compared to matched serum samples [103]. In the ZUMA-12 study which explored the role of CAR-T cell therapy in the first line setting for high-risk patients, no CNS relapses were observed after a median follow-up of 16 months [105]. This approach holds promise as a CNS active therapeutic option and warrants further investigation.